QLM3003 Placebo

DRUG2 trials

Sponsors

Qilu Pharmaceutical Co., Ltd.

Conditions

Atopic Dermatitis

Phase 1

Safety, Tolerability, and Pharmacokinetic Study of QLM3003 in Healthy Adult Subjects

CompletedNCT05932888

Qilu Pharmaceutical Co., Ltd.Atopic Dermatitis

Start: 2023-06-25End: 2023-08-30Updated: 2023-09-21

Phase 3

Efficacy and Safety Study of QLM3003 Ointment in Participants With Mild or Moderate Atopic Dermatitis

RecruitingNCT06880276

Qilu Pharmaceutical Co., Ltd.Atopic Dermatitis

Start: 2025-05-16End: 2027-05-31Target: 360Updated: 2025-08-26